Equities Analysts Offer Predictions for SLDB FY2026 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Solid Biosciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($2.13) for the year. Cantor Fitzgerald has a "Overweight" rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

Other equities analysts also recently issued research reports about the company. HC Wainwright boosted their target price on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Barclays cut their price objective on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. Piper Sandler reduced their target price on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. JMP Securities restated a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Friday, June 6th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Ten research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $14.90.

Solid Biosciences Stock Performance

SLDB stock traded down $0.07 during midday trading on Tuesday, reaching $4.51. 1,234,231 shares of the company traded hands, compared to its average volume of 1,144,908. The firm has a market capitalization of $349.59 million, a price-to-earnings ratio of -1.48 and a beta of 2.22. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $10.37. The business has a 50 day moving average of $3.26 and a 200-day moving average of $3.95.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06).

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SLDB. CWM LLC grew its position in shares of Solid Biosciences by 15,188.5% during the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock worth $29,000 after buying an additional 7,898 shares in the last quarter. Corton Capital Inc. purchased a new stake in Solid Biosciences in the fourth quarter worth about $41,000. Ground Swell Capital LLC bought a new position in Solid Biosciences during the 1st quarter worth about $42,000. Invesco Ltd. bought a new stake in shares of Solid Biosciences in the 4th quarter valued at about $49,000. Finally, Sei Investments Co. bought a new stake in shares of Solid Biosciences in the 4th quarter valued at about $52,000. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.